Ka Lai Yee
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, HIV Research and Treatment, Pneumocystis jirovecii pneumonia detection and treatment, Pharmacogenetics and Drug Metabolism, Sleep and Wakefulness Research
Most-Cited Works
- → Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective(2013)240 cited
- → Effects of Suvorexant, an Orexin Receptor Antagonist, on Sleep Parameters as Measured by Polysomnography in Healthy Men(2013)159 cited
- → Integrin-mediated signalling through the MAP-kinase pathway(2008)113 cited
- → The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold(2013)94 cited
- → Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man(2016)80 cited
- → Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans(2018)56 cited
- → A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment(2020)52 cited
- → The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects(2017)46 cited
- → Development of In Vitro–In Vivo Correlation for Amorphous Solid Dispersion Immediate-Release Suvorexant Tablets and Application to Clinically Relevant Dissolution Specifications and In-Process Controls(2015)45 cited
- → Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study(2016)44 cited